IP Library Granted Patent US 8,221,984
Granted Patent B2
US 8,221,984 · App. 12/079,592 · Granted Jul 17, 2012

Biomarkers for ovarian cancer

Assignees: Vermillion, Inc.; Board of Regents, The University of Texas System
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,221,984
App. No.
12/079,592
Granted
Jul 17, 2012
Kind
B2
Abstract

The present invention provides protein-based biomarkers and biomarker combinations that are useful in qualifying ovarian cancer status in a patient. In particular, it has been found that the biomarkers set forth in Table 1 are biomarkers for ovarian cancer. The biomarkers can be detected by SELDI mass spectrometry.

Claims (11)

1. A method for diagnosing ovarian cancer in a subject comprising:

(a) measuring in a urine sample from the subject Small MBL-associated protein C-terminal fragment (sMAP), and

(b) correlating the measurement with ovarian cancer, wherein an elevated level of sMAP as compared to the level of sMAP from a reference subject that does not have ovarian cancer indicates the subject has ovarian cancer, thereby diagnosing ovarian cancer in the subject.

2. The method of claim 1 , wherein sMAP is measured by mass spectrometry.

3. The method of claim 2 , wherein mass spectrometry is SELDI-MS.

4. The method of claim 1 , wherein sMAP is measured by immunoassay.

5. The method of claim 1 , wherein the correlating is performed by executing a software classification algorithm.

6. The method of claim 1 , further comprising: (c) reporting the diagnosis to the subject.

7. The method of claim 1 , further comprising: recording the diagnosis on a tangible medium.

8. The method of claim 1 , further comprising: (c) managing subject treatment based on the diagnosis.

9. The method of claim 8 , further comprising: (d) measuring sMAP after subject management and correlating the measurement with disease progression.

Assignments (6)
CHANGE OF NAME Recorded Aug 14, 2020
From: VERMILLION, INC.
To: ASPIRA WOMEN'S HEALTH INC.
Reel/Frame 053499/0896 →
SECURITY INTEREST Recorded Mar 24, 2016
From: VERMILLION, INC.
To: STATE OF CONNECTICUT DEPARTMENT OF ECONOMIC AND COMMUNITY DEVELOPMENT
Reel/Frame 038087/0448 →
RELEASE OF SECURITY INTEREST Recorded Jun 19, 2015
From: QUEST DIAGNOSTICS INCORPORATED
To: VERMILLION, INC.
Reel/Frame 035931/0792 →
SECURITY INTEREST Recorded Feb 2, 2010
From: VERMILLION, INC. (FORMERLY KNOWN AS CIPHERGEN BIOSYSTEMS, INC.)
To: QUEST DIAGNOSTICS INCORPORATED
Reel/Frame 023882/0519 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 23, 2008
From: BAST, ROBERT C.
To: TEXAS SYSTEM, THE UNIVERSITY OF, BOARD OF REGENT
Reel/Frame 021575/0230 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 23, 2008
From: FUNG, ERIC T.; PODUST, VLADIMIR; CLARKE, CHARLOTTE
To: VERMILLION, INC.
Reel/Frame 021575/0237 →
Continuity (3)
Provisional Application 60920274 · Mar 27, 2007
Provisional Application 61034469 · Mar 6, 2008
Related Publication 20090170208A1 · Jul 2, 2009